Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Genetic polymorphisms in tumour suppressor genes and genes encoding xenobiotic metabolising enzymes alter the activity of their corresponding enzymes and are important individual susceptibility factors for NSCLC. Because of the lack of information in literature, the aim of our study was to investigate the role of the tumour suppressor gene TP53 (Arg72Pro) and the xenobiotic metabolising CYP2E1*5B gene polymorphisms on the risk of NSCLC development. The study population consisted of 172 patients and 172 controls (156 men and 16 women in each group). Genetic polymorphisms were determined with real-time polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (PCR-RFLP). Multivariate analysis showed a significant association with NSCLC for the combination between the TP53 codon72 Arg/Pro and the Pro/Pro genotypes (OR 2.21, 95 % CI 1.39-3.51; p=0.001). We also analysed whether combinations of these gene variants with GSTM1, GSTT1, GSTP1 exon 5 (Ile105Val), and GSTP1 exon 6 (Ala114Val) gene polymorphisms were associated with the NSCLC risk. A significant increase in the risk was observed for the following combinations: TP53 codon72 variant with GSTM1 null (OR 2.22, 95 % CI 1.23-4.04; p=0.009), GSTT1 null (OR 2.98, 95 % CI 1. 49-5.94; p=0.002), and GSTP1 (Ala114Val) variant genotypes (OR 3.38, p=0.002). Further studies with larger samples are needed to verify these findings.
Lung cancer is the most common cancer type in the world, which affects men in particular. It is also the leading cause of death among cancers (1) . Histologically, about 80 % of lung cancers are non-small cell lung carcinomas (NSCLC). The inbuilt phase I and II biotransformation enzyme systems inactivate environmental carcinogens, especially those present in tobacco smoke, depending on the regulating polymorphisms. Epidemiological studies show that genetic differences and interactions among genetic variants might modify lung cancer susceptibility (2, 3) . Therefore, it is important to identify individual genetic and acquired factors that modify lung cancer risk in order to develop preventive strategies based on this information. This is particularly true for identifying polymorphisms of tumour suppressor genes and xenobiotic metabolising enzyme genes. The TP53 tumour suppressor gene is an essential regulator of the cell-cycle arrest, DNA repair, and apoptosis (4) . An important single nucleotide polymorphism detected in TP53 is Arg72Pro. This allele has been shown to decrease the activity of the corresponding protein, which is crucial for the apoptotic function of TP53 (5, 6) . Recent studies have reported the association between this polymorphism and lung cancer (7) (8) (9) (10) (11) .
CYP2E1 is an important phase I biotransformation enzyme that transforms N-nitrosamines, vinyl chloride, and benzene in tobacco smoke into mutagenic and carcinogenic metabolites (12) . In NSCLC patients it has been found to be overexpressed (13) . However, its CYP2E1*5B allele has been shown to reduce enzyme activity and microsomal oxidation capacity (14, 15) .
The complex pathways of (pro)carcinogen metabolism and the possible interactions between the genes encoding enzymes and TP53 protein clearly indicate the need for their combined assessment as predisposing factors for NSCLC development. However, current findings on the overall impact of TP53, CYP2E1, and GST polymorphisms on NSCLC are limited and controversial (16) (17) (18) . The aim of this study was to learn more about these impacts by investigating: a) the association between NSCLC risk and TP53 (Arg72Pro) and CYP2E1*5B polymorphisms either alone or in combination and b) possible gene interactions as risk modifiers for NSCLC by combining TP53 (Arg72Pro) and CYP2E1*5B polymorphisms with phase II enzyme coding gene polymorphisms GSTM1, GST1, GSTP1 (Ile105Val) (rs1695), and GSTP1 (Ala114Val) (rs1138272) that we have previously genotyped in NSCLC patients (19) .
PARTICIPANTS AND METHODS
This case-control study included 344 participants, 172 of whom were histologically confirmed NSCLC patients and 172 were matching controls by gender and mean age (±3 years). All NSCLC patients were enrolled at the Ataturk Pulmonary Diseases and Thoracic Surgery Hospital from February 2002 to November 2005. Their clinical data were collected from medical records. The staging and histological sub-typing of the lung carcinomas followed the international staging system for lung cancer and World Health Organisation histological classification of lung tumours (20) . All other lung cancer types were excluded from the study.
Each patient had an interview to answer a detailed questionnaire about sociodemographic and history of smoking information. Pack years were calculated by multiplying packs smoked per day with years as a smoker.
The control group was recruited at a local healthcare centre and consisted of volunteers who were informed about the study during their routine health check-ups. The exclusion criteria were history of malignancy, pregnancy, chronic diseases, and diagnosed cancer of any type. Controls also completed a detailed questionnaire about smoking habits, work, and health history. The category of former smokers included NSCLC patients who had quit smoking at least one year before diagnosis and controls who had quit smoking at least one year before the interview. All participants were Caucasian and gave informed consent to participate in writing. The study was approved by the Medical Ethics Board of the Ataturk Pulmonary Diseases and Thoracic Surgery Hospital.
Genomic DNA samples for genetic polymorphism analysis were obtained from the blood drawn into coded 10 mL heparinised tubes and isolated with a DNA purification kit according to the manufacturer's instructions (Promega, Fitchburg, WI, USA). Isolated DNA was kept at -20 °C until use.
The TP53 (Arg72Pro) polymorphism (rs1042522) was identified using the real-time polymerase chain reaction (PCR) as described by Talseth et al. (21) . The CYP2E1*5B (RsaI/PstI, rs3813867/rs2031920) polymorphism was identified with the PCR-restriction fragment length polymorphism (PCR-RFLP) method described by Hayashi et al. (15) and confirmed by real-time PCR as described by Choi et al. (22) .
Laboratory personnel were not informed about the source of DNA samples. For quality control we randomly selected 10 % of the samples, and the repeated genotyping procedures gave 100 % concordance. All genotyping data were independently reviewed by two authors.
Statistical analysis
For the comparison of mean age and pack-years between cases and controls we used Student's t-test. Multivariate logistic regression was used to calculate odds ratios (OR) between genotypes and NSCLC and 95 % confidence intervals adjusted for age, gender, and smoking status. Gene-smoking interaction adjusted for age was tested on the multiplicative scale by entering product terms in the multivariate logistic models. P values below 0.05 were considered significant. For statistical analysis we used the SPSS 15.0 software package (SPSS Inc., Chicago, IL, USA). Table 1 shows the demographic information for all participants. NSCLC patients had significantly higher values of pack years smoked than controls (56 and 15 respectively) (p<0.05). Table 2 shows the distribution of the TP53 and CYP2E1 genotypes and adjusted ORs for NSCLC. When calculating the ORs, we took wild-type or positive genotypes as reference. As we did not detect the homozygous mutant genotype (*5B/*5B) (c2/c2) of CYP2E1 in either group, we combined heterozygous and homozygous genotypes of other polymorphisms for the statistical analysis throughout the study and have presented the results accordingly. The (Table 3) .
RESULTS
We did not analyse the risk of histological subtypes with combined genotypes because of the small number of subjects in each subgroup.
As for the multivariate analysis of gene interactions with cigarette smoking, we found no significant association with the NSCLC risk (data not shown).
DISCUSSION
This is the first study demonstrating the association between TP53 (Arg72Pro) polymorphism and the NSCLC risk in a Turkish population. Individuals carrying this variant had a 2.2 times higher risk than controls. TP53 polymorphisms have widely been studied in NSCLC, but the results are contradictory. Three studies reported a significantly increased risk (23) (24) (25) , one (26) reported an insignificant risk increase, and three (9, 17, 27) (25), we, however, believe to be on the right track, since this TP53 variant has lower activity in apoptosis and its association with an increased NSCLC risk is plausible.
Studies investigating the effect of the CYP2E1*5B polymorphism on NSCLC risk also reported inconsistent results (17, (28) (29) (30) (31) (32) .
After the analysis of NSCLC subtypes, we found that the variant (Pro) allele carriers of TP53 codon72 were significantly associated with the risk of SCC but not AC. We found a significant association between the TP53 codon72 heterozygous (Arg/Pro) genotype and the risk of NSCLC (OR 2.87; 95 % CI 1.70-4.85; p=0.001). The association was not significant between TP53 codon72 mutant (Pro/Pro) genotype and NSCLC (OR 1.34, 95 % CI 0.52-3.49; p=0.546), possibly due to the low number of Pro/Pro genotype carriers in both the NSCLC (n=13) and control group (n=15). When we combined the TP53 codon72 Arg/Pro and Pro/Pro genotypes, we found a significant association between NSCLC risk and the genotypes containing variant allele, as shown in Table 2 . The analysis of NSCLC subtypes showed a significant risk of squamous cell carcinoma and unspecified NSCLC in patients carrying the variant (Pro) allele of the TP53 codon72 (OR 3.50; 95 % CI 1.76-6.99; p=0.001 and OR 3.22, 95 % CI 1.49-6.95; p=0.003, respectively) but not of adenocarcinoma (1.34, 95 % CI 0.72-2.51; p=0.360). Table 3 shows no significant difference between TP53 and CYP2E1 gene interactions and the risk of NSCLC (top results). We then looked further to find if these variant genotypes would be associated with increased NSCLC risk if combined with the GSTM1, GSTT1, and GSTP1 polymorphisms from our earlier study (19) and found a significant association for TP53 codon72 Arg/Pro and Pro/ Pro in combination with the GSTM1 null genotypes. A similar significant association with NSCLC risk was found for the combinations of TP53 codon72 Arg/Pro and Pro/ Pro with the GSTT1 null and the GSTP1 (Ala114Val) genotypes (Table 3) .
In contrast, the combination of TP53 codon72 with the GSTP1 (Ile105Val) variant was not significantly associated with the NSCLC risk, nor were the CYP2E1 genotype but not of SCC. These inconsistent findings need to be clarified in larger future studies.
Our analysis of the potential effect of gene interactions on NSCLC risk was motivated by the fact that cancer is a complex, multigene process and that individual susceptibility to cancer varies. The association between NSCLC risk and the TP53 (Arg72Pro) polymorphism in combination with genes encoding enzymes involved in tobacco-specific carcinogen metabolism has not been well studied so far. In our study, the combination of the TP53 codon72 and the CYP2E1*5B variants was not significantly associated with NSCLC. In Asian populations, the CYP2E1*5B polymorphism was found to be associated with lower NSCLC risk (32) . Although this variant allele was relatively rare in our Caucasian participants compared to Asian populations, it may have countered the risk increased by the TP53 codon72 variant, because their combination was not associated with NSCLC. However, we cannot exclude the possibility that the observed findings are pure chance.
We have also analysed the interactions between TP53 and CYP2E1 gene polymorphisms and the GST gene (GSTM1, GSTT1 and GSTP1) polymorphisms that we had previously determined in the same patients in our 2012 study (19) to see whether they may affect the NSCLC risk. Our results confirm the findings of Klinchid et al. (33) , who found a significant association between the TP53 codon72 variant and GSTM1 null combination and NSCLC. The highest risk of NSCLC was associated with the TP53 codon72 variant plus GSTP1 (Ala114Val) variant combination (OR=3.38). This combination increases the risk of NSCLC 1.5 times over either variant alone. These findings are consistent with the effect of the mutant TP53, which impairs the apoptosis of transforming tumour cells, while lower GST variant activity insufficiently detoxifies carcinogenic chemicals.
What may limit the interpretation of our findings is a relatively small sample size, yet they clearly point that the TP53 (Arg72Pro) polymorphism alone and in combination with GSTM1, GSTT1, or GSTP1 (Ala114Val) may increase the risk of NSCLC, the last combination in particular. Further studies with larger samples are needed to verify these findings.
